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Tuning a Multiple Classifier System for Side Effect Discovery using
Genetic Algorithms
Jenna M. Reps, Uwe Aickelin and Jonathan M. Garibaldi
Abstract—In previous work, a novel supervised framework
implementing a binary classifier was presented that obtained
excellent results for side effect discovery. Interestingly, unique
side effects were identified when different binary classifiers
were used within the framework, prompting the investigation
of applying a multiple classifier system. In this paper we
investigate tuning a side effect multiple classifying system using
genetic algorithms. The results of this research show that the
novel framework implementing a multiple classifying system
trained using genetic algorithms can obtain a higher partial
area under the receiver operating characteristic curve than
implementing a single classifier. Furthermore, the framework
is able to detect side effects efficiently and obtains a low false
positive rate.
I. INTRODUCTION
S
IDE EFFECTS of prescription drugs are a common
occurrence that often lead to patient morbidity and
mortality. When there is an association between a medical
event (e.g., sickness, rash and weakness) and a drug, this
is termed an adverse event (AE). When the relationship is
proven to be causal (i.e., the drug causes the medical event),
it is referred to as an adverse drug reaction (ADR).
As a large quantity of medical data are often stored
in databases, numerous methods have been presented that
make use of medical databases with the aim of identifying
ADRs efficiently [1], [2]. Unfortunately, the majority of these
methods work by finding medical events that are highly
associated to a drug, therefore, rather than detecting ADRs
they detect AEs. This has lead to the methods having high
false positive rates [3], [4] as the majority of associations
are not causal. Recent research has focused on using super-
vised techniques such as logistic regression [5] to reduce
the impact of confounding (i.e., when a hidden variable is
responsible for the association). These supervised methods
aim to distinguish between associations that are causal or
non-causal by finding alternative causes of the medical event.
Unfortunately, this requires generating a large number of
regression models and also requires additional knowledge
of possible confounders (e.g., other possible causes of the
medical event). Consequently, these methods are often slow
and dependant on current knowledge. Alternatively, a recent
framework, side effect classifier (SEC), has been proposed
that applies a single supervised classifier to identify ADRs
efficiently [6] and the results suggest this framework is less
susceptible to confounding.
Jenna M. Reps, Uwe Aickelin and Jonathan M. Garibaldi are with the
School of Computer Science, The University of Nottingham, UK (email:
{jenna.reps, uwe.aickelin, jonathan.garibaldi }@nottingham.ac.uk).
The SEC framework generates attributes inspired from the
Bradford Hill causality criteria [7], a collection of factors
that are often considered to determine causality, and uses
these attributes and knowledge of existing ADRs to train a
classifier capable of identifying new ADRs. The framework
was shown to identify ADRs with a low false positive rate
and is highly efficient once the classifier is trained. Different
binary classifiers can be implemented within the framework,
depending on the quantity of labelled data (this depends on
the current knowledge of ADRs). It was noticed that the
SEC framework implementing a different binary classifier
will in general detect different ADRs, suggesting there is
diversity between the classifiers. Inspired by this diversity, in
this paper we investigate whether using a type of ensemble,
called a multiple classifier system, that combines predictions
obtained from multiple classifiers is better than using a single
classifier’s prediction within the framework. The multiple
classifier system classifies each data-point corresponding to
a drug-medical event pair as an ADR or non-ADRs based
on a weighted combination of each individual classifiers
confidence of the data-point belonging to the ADR class. The
weights are determined by using genetic algorithms to search
for the values that optimise the SEC framework’s ability to
detect ADRs.
This paper continues are follows. The next section gives an
overview of genetic algorithms, multiple classifier systems
and pharmacovigilance, including the SEC framework. In
section III, we described the longitudinal medical database
used in this research, known as The Health Improvement
Network (THIN) database (www.thin-uk.com), and highlight
current issues with the data. Section IV describes the genetic
algorithm method used to determine the classifier weights
implemented by the multiple classifier system. The results
of the framework implementing the trained multiple classifier
system is compared with the individual classifiers’ results and
are presented and discussed in section V. The paper finishes
with the conclusions in section VI.
II. BACKGROUND
A. Genetic Algorithms
Genetic algorithms are probabilistic search procedures in-
spired by the natural process of evolution [8]. The algorithm
is an iterative process that initially starts with a population
of candidate solutions that are randomly generated, and
then these candidate solutions are evolved. Each candidate
solution has a set of genotypes (e.g., parameter values)
and the set of genotypes determine the candidate solution’s
fitness. During each iteration, a new generation of candidate
Fig. 1. The schema of a multiple classifier system.
solutions are created by recombination and mutation of
the previous candidate solutions’ genotypes based on their
fitness.
B. Multiple Classifier System
The term ensemble is used to describe a composition of
multiple classifiers. A type of ensemble that consists of a
composition of various different classifiers has frequently
been termed a multiple classifier system [9] rather than
called an ensemble. This is to help distinguish between a
combination of the same classifier trained with different
perspectives (e.g., combining decision trees that are trained
using different independent variables) and a combination of
different classifiers (e.g., combining a SVM, a random forest,
a neural network and a logistic regression model). Fig. 1
illustrates a multiple classifier system that combines the out-
put of multiple single classifiers to generate a single output.
The aim of a multiple classifier system is the take advantage
of diversity between classifiers to improve the classifying
accuracy while maintaining efficiency. Multiple classifier
systems have been successfully implemented in numerous
machine learning tasks including diagnosing melanoma [10],
classifying breast lesions [11] and detecting naked bodies in
images [12]. In the previous examples, combining multiple
classifiers, under a suitable weighting scheme, was shown to
improve performance compared to a single classifier.
As the classifiers used to identify ADRs within the SEC
framework appear to be diverse, implementing a multiple
classifier system that combines all the classifiers may im-
prove the detection of ADRs.
C. Previous Pharmacovigilance
Pharmacovigilance is the study of prescription drug side
effects. One important part of pharmacovigilance is the
process of detecting drug side effects after the drugs have
been approved and marketed. Identifying drug side effects is
a difficult task due to the majority of side effects relying on
multiple factors, so it is common for some side effects to
be observed rarely. Clinical trails are unable to identify the
majority of side effects prior to marketing due to them only
involving a small number of patients and being conducted
Fig. 2. An example of an SRS database entity relationship diagram
Fig. 3. Illustration of how the reports in the SRS database contain direct
links between drugs and medical events. Each report within the database
consists of an observation of a patient taking a drug and then experiencing
the medical event sometime after.
under unrealistic conditions [13]. For example, patients in-
volved in clinical trials are unlikely to take other drugs during
the trial, so drug interactions can not be analysed.
In general, the most widely implemented pharmacovigi-
lance techniques have been developed for a specific type of
medical database known as the spontaneous reporting system
(SRS) databases [14]. These databases consist of all the
reports made by medical staff or the general public relating to
a suspected ADR. The general design of the SRS databases is
illustrated in Fig. 2. The SRS databases contain natural links
between drugs and medical events, see Fig. 3. Sometimes
additional information about the patient is included into the
report, such as age and gender, but this is not compulsory.
The techniques for detecting ADRs look for medical events
linked disproportionally more to the drug than expected [15].
Unfortunately, due to the reporting being voluntary, many
ADRs may not be reported, and it is possible that some
rare ADRs may never be noticed. This under-reporting can
prevent the early detection of ADRs and this means patients
are put at risk for longer. In addition, there are known data
quality issues such as missing, duplicated or incorrect data
[16].
Due to the limitations associated with the SRS databases,
recent work has focused on using different types of medical
databases [17]. One example is the longitudinal health-
Fig. 4. An example of a longitudinal healthcare database entity relationship
diagram
care databases. These databases contain medical information
about patients often spanning many years and it is common
for them to contain records for millions of patients. As this
type of database does not rely on voluntary reporting, it
presents a unique perspective for signalling ADRs. However,
it has been shown to suffer from different limitations. The
main limitation is that there are no clear links between
drugs and medical events within the data itself, so potential
links are inferred by finding the medical events that occur
shortly after the drug in time. This is illustrated in Fig. 5.
Unfortunately, the majority of the drug and medical events
linked by time are associated but do no correspond to ADRs,
and it has proved difficult for unsupervised algorithms to
distinguish between the non-causal and causal relationships.
In [18], the authors presented a semi-supervised algorithm
that requires a user to input a drug of interest and then returns
a ranked list of medical events. The higher a medical event is
ranked by the algorithm, the more likely that medical event
corresponds to a rare ADR of the specified drug of interest.
The algorithm generated the data by extracting attributes
that are insightful for ADR detection from a longitudinal
healthcare database and determined labels for some medical
events by mining online medical websites. The labelled and
unlabelled data were then used to clusters similar medical
events into either an ADR cluster, an indicator (a cause of
taking the drug) cluster or a noise cluster. Medical events
assigned to the noise cluster were filtered, and the remaining
medical events where ranked based on how often they
occurred after the drug divided by how often they occurred
before the drug multiplied by a cluster dependent weight.
The success of the semi-supervised algorithm them
prompted the idea of generating causal inference based
attributes for a selection of drug-medical event pairs that
are definitively known ADRs or non-ADRs [19] and using
this data to train a classifier that can then be used to pre-
dict new ADRs. One such supervised framework generated
attributes based on the counterfactual theory of causality
[20], whereas another framework, SEC, generated attributes
based on the Bradford Hill causality criteria. Rather than
mining online forums for the known ADR and non-ADR
labels, both frameworks used an online resource that contains
lists of ADRs that were mined from drug packaging. Both
supervised frameworks demonstrated excellent performance
and previous results suggest supervised techniques may help
improve current pharmacovigilance.
1) SEC Framework: The previously presented SEC
framework is a supervised algorithm for detecting ADRs.
The algorithm automates the technique of inferring causality
via the Bradford Hill causality criteria, as this technique is
commonly applied to assess whether a side effect is caused
by a drug or not. The SEC framework requires three steps.
The first step is data generation where suitable labelled
data are extracted for each drug-medical event pair that
represent a possible acute ADR. The second step is training
a binary classifier using the labelled data to classify each
drug-medical event pair as an ADR or non-ADR, and the
final step is applying the trained classifier to new unlabelled
data.
Step 1) Data generation
As we are interesting in detecting acutely occurring ADRs,
we find the drug-medical event pairs that are possible ADRs
by investigating the medical events that occur within a month
of a drug being prescribed. To train a binary classifier
we need a set of attribute vectors xi ∈ R
n and their
corresponding class yi ∈ {−1, 1}. In the SEC framework,
each data point corresponds to a drug-medical event pair
of interest, where the ith drug-medical event pair has the
attribute vector xi and class yi. Therefore, to generate the
training data, the first step is to identify the drug-medical
event pairs of interest, the second step is to determine their
labels and the final step is to calculate their attributes.
To identify the drug-medical events pairs of interest, we
restrict out attention to a set of specified drugs, denoted by
D. For each drug di ∈ D, we use temporal relationships
to identify the risk medical events of di (RMEdi ). The
risk medical events of di are the medical events that were
observed during the month after a prescription of di for one
or more patients, RMEdi = {medical events | the medical
event occurs within a month of di for one or more patients }.
The drug-medical event pairs of interest are all the possible
combinations of d-e, where d ∈ D and e ∈ RMEd. The
drug-medical event pairs of interested with labels are then
determined. For the ith drug-medical event pair, if the medical
event is labelled as a known side effect of the drug within
the online drug resource known as SIDER [21], then the
pair is labelled as an ADR (yi = 1). Alternatively, if the
medical event cannot possibly correspond to an acute ADR
(e.g, the medical event is ‘cancer’, ‘menopause’ or ‘death of
family member’), the drug-medical event is labelled as a non-
ADR (yi = −1). Any drug-medical event pair neither listed
on SIDER as corresponding to a known ADR nor clearly a
non-ADR is ignored as the pair has no definitive label.
For the ith drug-medical event pair labelled as an ADR or
non-ADR, we calculate the Bradford Hill causality criteria
based attributes, described in [6] and denote the vector
consisting of these attributes by xi. The attributes are derived
Fig. 5. An example of inferring a link between a drug and medical event within a longitudinal healthcare database. The medical events are represented
by circles and the drugs represented by squares. The potential acute ADRs are the medical events observed during the [t0,t1] time period centred around
the prescription.
from a selection of the Bradford Hill causality criteria:
• Association strength: How strong the association be-
tween the drug and medical event is.
• Temporality: Does the drug precede the medical event
or the other way?
• Specificity: How specific the medical event is, or how
similar patients experiencing the medical event are. item
Biological gradient: Measures whether the probability
of the medical event increases as the drug dosage
increases.
• Experimentation: Does the medical event start and stop
when the drug starts and stops?
In summary, for the ith labelled drug-medical event pair
we have (xi, yi), where xi is the Bradford Hill causality
attributes and yi = 1 when the i
th drug-medical event pair is
a known ADR and yi = −1 when the i
th drug-medical event
pair is a known non-ADR. The complete set of labelled data
is denoted by X , where X = {(xi, yi)}.
Step 2)Training a binary classifier
The labelled data are then used to train a binary classifier
(the choice of classifier is determined by the user as any
classifier can be used within the framework),
f : X → Y ; f(xi)→ {−1, 1} (1)
where f(xi) = −1 means the drug-medical event pair
is classified as a non-ADR and f(xi) = 1 means the
drug-medical event pair is classified as an ADR. The chosen
classifier is trained using ten-fold cross validation to reduce
overfitting. In previous work [6], the random forest classifier
was found to perform better than a support vector machine,
a logistic regression and a naive Bayes classifier.
Step 3)Applying trained classifier
The trained classifier is then applied to the attribute vector x∗
for a new drug-medical event pair, and the prediction f(x∗)
is returned.
For evaluating the framework, the labelled data are par-
titioned into training/testing data and validation data. The
training/testing data are used to train the classifier and the
validation data are used to evaluate the performance of the
trained classifier by comparing the predicted class with the
true class.
III. MATERIALS
The THIN database contains temporal medical data for
over 11 million patients (approximately 4 million currently
active patients). The data is anonymised, so each patient is
represented by a unique patient ID rather than the patients
real name. There are three main tables within the THIN
database, the patient table, the medical table and the therapy
table, see Figs. 6-8. The patient table contains personal
information about each patient in the database including their
year of birth, their gender and their date of registration. The
therapy table contains timestamped records of each patient’s
drug prescription history, so each record includes the patient
ID, the date of the prescription and information about the
prescription (drug details and dose details). The medical
table is similar to the therapy table but contains timestamped
records of each patient’s medical event history (i.e., illnesses,
diseases, laboratory tests and administrative events), so a
typical record contains the patient ID, the date of the medical
event and the medical event information, recorded via the
READ codes.
Each READ codes consist of five elements from the
alphabet {a − z,A − Z, 1 − 9, }˙ and they have a hierarchal
structure. The depth of a node within a tree is the length of
Fig. 6. The patient table within the THIN database.
Fig. 7. The medical table within the THIN database.
the minimum path from the node to the root. Unfortunately,
the READ codes have redundancies and the same medical
event can be represented by various distinct READ codes.
This can cause issues for data miners, however the SEC
algorithm generates attributes specifically to prevent this
issue having a negative effect on its ability to detect ADR.
IV. METHODOLOGY
In this paper we are developing a multiple classifier system
to be implemented within the SEC framework and com-
paring its ability to detect side effects with the framework
implementing a single classifier. Therefore, in this section the
methods used to analyse the single classifier framework and
the multiple classifier system framework are both described.
To evaluate each framework, we determine all the la-
belled drug-medical event pairs correspond to the 25 drugs:
nifedipine, amlodipine, felodipine, nicardipine, verapamil,
Fig. 8. The therapy table within the THIN database.
ciprofloxacin, ofoxacin, norfloxacin, nalidixic acid, moxi-
floxacin, fluconazole, itraconazole, posaconazole, voricona-
zole, ibuprofen, fenoprofen, ketoprofen, celecoxib, flurbipro-
fen, nabumetone, naproxen, budesonide, beclometasone, hy-
drocortisone and prednisolone. These labelled data are com-
posed of the 30 Bradford Hill causality criteria derived
attributes for each drug-medical event data-point and a label
specifying whether the drug-medical event data-point is listed
as an ADR on SIDER or one of the manually selected non-
ADRs.
There were a total of 5710 drug-medical event data points
with known labels corresponding to the 25 chosen drugs. The
labelled data were partitioned into training/testing data XT
(80% of the labelled data) and validation data XV (20% of
the labelled data). The training/testing date were used to train
the classifier or multiple classifier system and the validation
data were used to evaluate the framework implementing the
single classifier or multiple classifier system.
The measure used to determine the effectiveness of each
framework is the area under the receiver operating charac-
teristic curve. This measure corresponds to the probability
of a drug-medical event pair known to be an ADR being
assigned a higher confidence of being within the ADR class
by the framework than a drug-medical event pair known to
be a non-ADR [22]. In particular, we restrict out attention
to a partial area, as we are only interested in the section of
the curve where few drug-medical event pairs are classed
as side effects [23]. When many drug-medical event pairs
are classed as ADRs, there are likely to be many non-ADRs
pairs incorrectly classed as ADRs and this is undesirable.
The partial area under the curve that we are interested in is
denoted by pAUC[0.9,1] and a more detailed explanation of
how the measure is calculated can be found in section IV-C.
A. SEC Framework: Single Classifier
To analyse the single classifier framework, the SEC frame-
work implementing either a random forest, support vector
machine, logistic regression, naive Bayes or k-nearest neigh-
bours classifier is trained using ten-fold cross validation on
the training/testing data XT . The trained classifier is denoted
by f : R30 → {−1, 1}, where f(xi) = −1 represents the i
th
drug-medical event pair being classifier as a non-ADR and
f(xi) = 1 represents the i
th drug-medical event pair being
classifier as an ADR.
B. SEC Framework: Ensemble Classifier
The multiple classifier system framework requires train-
ing multiple classifiers and learning the optimal weighted
combination of the classifiers. In this framework, after the
training data is generated, the data is firstly used to train
various classifiers and then used to determine a weighted
combination of all the classifier.
1) Training the classifiers: Five classifiers (random forest,
support vector machine, logistic regression, naive Bayes and
k-nearest neighbours) are trained via ten fold cross validation
to determine the optimal parameters that maximise the partial
TABLE I
THE DIFFERENT CLASSIFIERS USED BY THE MULTIPLE CLASSIFIER SYSTEM AND THEIR OPTIMAL PARAMETERS.
Classifier Parameters :-(grid search range) Optimal Parameters
f1: Random Forest mtry:-[1,30] mtry=11
f2: Support Vector Machine (Radial) sigma:-(0,1], C:-(0,10] sigma=0.0978, C=6.1624
f3: K-Nearest Neighbours K:-[1,100] K= 17
f4: Logistic Regression decay:-[0,10] decay=0
f5: Naive Bayes fL:-[0,1], usekernel:-{ TRUE,FALSE } fL=0, usekernel=TRUE
area of interest under the curve (pAUC[0.9,1], see section IV-
C) using the training/testing XT set. Each classifier is trained
using a grid search over suitable parameter values, these can
be seen in Table I and the chosen parameter values are also
listed.
For each trained classifier fi, we can also extract the
classifiers confidence that the drug-medical event is in the
ADR class, this is denoted by ci : R
30 → [0, 1]. So ci(xj) is
the confidence of the i th classifier that the j th drug-medical
event pair is an ADR.
2) Determining the weights: Using these confidence func-
tions, genetic algorithms are applied to find the optimal
weights βi, i ∈ [1, 5] for the multiple classifier system that
determines the class of the jth drug-medical event pair by,
f6(xj) =
{
1 if
∑
i βici(xj) ≥ α ∈ (0, 1)
−1 otherwise
(2)
The value α is the natural threshold and this controls the
stringency of the multiple classifier system.
The weights are determined by implementing a genetic
algorithm with a mutation rate of 0.1 and applying elitism
with a candidate population size of 1000 until convergence,
see Table II for full details. The fitness of each weight
vector (β) is the ten fold cross validation average of the
the partial AUC over the specificity range [0.9,1] for the
multiple classifier system based on that weight scheme on
the training/testing set. The optimal weight vector was,
β = (β1, β2, β3, β4, β5)
= (0.701, 0.314, 0.002, 0.026, 0.012)
(3)
where c1() is random forest, c2() is support vector machine,
c3() is K-nearest neighbours, c4() is logistic regression and
c5() is naive Bayes.
C. Evaluation
The framework implementing a single trained classifier or
the multiple classifier system is then applied to the validation
set and the prediction of each data-point in the validation set
is compared with the truth. The number of true positives
(TP), false positives (FP), false negatives (FN) and true
negatives (TN) are calculated as follows,
TP: |{i|yi = f(xi) = 1}|
FP: |{i|yi = −1, f(xi) = 1}|
FN: |{i|yi = 1, f(xi) = −1}|
TN: |{i|yi = f(xi) = −1}|
Using the above values, the accuracy, precision, sensitivity,
and specificity can be calculated,
Sensitivity = (TP)/(TP+FN)
Specificity = (TN)/(TN+FP)
Accuracy = (TP+TN)/(TP+FP+FN+TN)
Precision = (TP)/(TP+FP)
(4)
The receiver operating characteristic (ROC) curve is gener-
ated by potting the sensitivity against 1 minus the specificity
and the AUC is the area under this curve. The AUC measures
the general ability of a classifier rather than only considering
how well it does it at its natural threshold and is a fairer mea-
sure for comparing different classifiers. The pAUC[0.9,1] is
the partial area under the ROC curve, between the specificity
values of 0.9 − 1, this value is useful as we are interested
in the classifiers ability when the specificity is high and the
number of of false positives is low.
V. RESULTS & DISCUSSION
The results are presented in Table III and ROC plots
for the framework implementing the range of classifiers
or the multiple classifier system can be seen in Fig. 9.
The optimal value for α (the multiple classifier system’s
natural threshold) was found to be α = 0.4381. It can be
seen that the framework implementing a multiple classifier
system (f6) obtained a superior accuracy, sensitivity and
pAUC[0.9,1] than the framework implementing any single
classifier. However, using a bootstrap test to compare the
pAUC[0.9,1]s [24] of the random forest and the multiple
classifier system at a 5% significance level, the pAUC[0.9,1]
was not shown to be significantly different (p-value=0.499).
The highest precision and specificity values were obtained by
the framework implementing a support vector machine and
not the multiple classifier system. This is probably due to the
multiple classifier system being optimised specifically for the
partial AUC. If the precision or specificity was deemed to be
more important, different weights could be calculated by the
genetic algorithm to optimise the multiple classifier system
for the desired measure (e.g., precision or specificity).
The ensemble weights do not necessarily reflect the impor-
tance of the classifier within the ensemble, as each classifier
has varying ranges for its confidence function values. It may
be useful to normalise the confidence function values prior
to determining the optimal ensemble weights. If the classifier
confidence weights were normalised, then the ensemble
weights would correspond to the importance of the classifier
TABLE II
THE GENETIC ALGORITHM PARAMETERS.
Population
size
Crossover type Mutation type Elitism
used
Selection criteria Initialisation Stopping
criteria
1000 Local arithmetic
crossover
Uniform random
mutation
True Fitness proportional selection
with fitness linear scaling
Uniformly
chosen from
[0,1]
After 500
iterations
TABLE III
THE RESULTS OF THE SEC FRAMEWORK IMPLEMENTING A SINGLE CLASSIFIER OR MULTIPLE CLASSIFIER SYSTEM FOR THE VALIDATION SET.
Framework classifier Accuracy Precision Sensitivity Specificity pAUC[0.9, 1]
f1: Random Forest 0.930 0.789 0.380 0.989 0.769
f2: Support Vector Machine 0.921 0.809 0.241 0.994 0.710
f3: K-Nearest neighbours 0.917 0.729 0.222 0.991 0.695
f4: Logistic Regression 0.086 0.085 0.861 0.003 0.693
f5: Naive Bayes 0.912 0.577 0.354 0.972 0.710
f6: Multiple Classifier System 0.933 0.782 0.430 0.987 0.772
and this would then help indicate which of the classifiers was
most influential within the ensemble. This knowledge could
be used to remove classifiers that had little influence.
The advantage of ensemble approaches rather than relying
on any individual classifier is that they generally reduce the
classifier’s variance. This is useful for ADR detection, as
the training set is likely to change and grow as new ADRs
are discovered. An ensemble approach for ADR detection
is also useful, as previous results have shown that each
classifier tends to make different mistakes, so the ensemble
can overcome an individual classifiers misclassification. This
is the likely reason why the ensemble obtained an improved
performance. However, the disadvantages are that the en-
semble is computationally longer due to the requirement of
training multiple classifiers and then tuning the ensemble
weights. Although the multiple classifier system improved
the accuracy and pAUC[0.9,1] compared to each single
classifier, the improvement was not significant. This may
suggest that when the training data is sufficiently large to
enable good performance from a single classifier, the small
benefit in performance of the ensemble is not enough to
overcome the extra cost of complexity. It would be interesting
to investigate how the ensemble performs relative to each
individual classifier at various training set sizes.
VI. CONCLUSIONS
In previous work, it was shown that different classifiers
detected different side effects. In this paper we combined
various classifiers with the aim of improving the overall
discovery of side effects. The classifiers were combined using
genetic algorithms to tune a multiple classifier system that
can be used within a side effect discovery framework. We
then compared the side effect discovery framework imple-
menting a multiple classifier system with the framework im-
plementing a single classifier. The results show that a larger
partial AUC can be obtained by a multiple classifier system
that integrates multiple diverse classifier by calculating a
Fig. 9. The ROC plots for the frameworks ability to detect ADRs when
implementing the different classifiers.
weighted aggregate of their confidences that a data-point
belongs to the class ADR. This research presents a novel
useful application of genetic algorithms.
Possible areas of future work could investigate using a
suitable evolutionary algorithm to tune each of the individual
classifiers rather than using a grid search (i.e., a selection of
values for each parameter in input and the search is done over
all possible parameter combinations), as this may increase
their individual performance in addition to the multiple
system classifiers performance.
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